SGLT2 inhibitor 'shows similar efficacy' for men and women with HFrEF

The results are from a prespecified analysis of the pivotal DAPA-HF study

Dapagliflozin reduces the risk of worsening heart failure and death similarly in both sexes in patients with heart failure with reduced ejection fraction (HFrEF), researchers say.

Breathless senior Asian woman

And symptoms, function, and quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) improved to similar degrees in men and women, they report in JAMA Cardiology.

In a prespecified secondary analysis of the DAPA-HF study, UK-led researchers